Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
163 hedge funds and large institutions have $1.74B invested in Intercept Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 56 increasing their positions, 47 reducing their positions, and 16 closing their positions.
100% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 16
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
48% more call options, than puts
Call options by funds: $98.4M | Put options by funds: $66.6M
44% more capital invested
Capital invested by funds: $1.21B → $1.74B (+$535M)
19% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 47
11% more funds holding
Funds holding: 147 → 163 (+16)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$55.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$41.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.1M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$75.5M |
| 2 |
JP Morgan Chase
New York
|
-$26.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.3M |
| 4 |
SM
Senvest Management
New York
|
-$12.9M |
| 5 |
Millennium Management
New York
|
-$11.6M |
ICPT Hedge Fund Activity: Q2 2018 in Review
163 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2018, worth a combined $1.74B — up 44% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ICPT positions and 16 closed out — a net gain of 16 holders — while 56 added to existing stakes and 47 trimmed.
The largest buyer was BlackRock, adding an estimated $55.3M. The largest seller was Capital World Investors, cutting an estimated $75.5M.
- 163 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2018, up from 147 in Q1 2018.
- Funds reported $1.74B of Intercept Pharmaceuticals, Inc. stock for Q2 2018, up 44% quarter-over-quarter.
- 32 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2018 and 16 closed out, a net change of +16 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2018 was BlackRock, an estimated $55.3M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q2 2018 was Capital World Investors, an estimated $75.5M sold.
Based on aggregated 13F filings for Q2 2018.